Roche's Gazyva secures FDA nod for idiopathic nephrotic syndrome, extending autoimmune pivot

Roche's Gazyva received FDA approval for idiopathic nephrotic syndrome, marking the first new treatment for this rare autoimmune kidney disease in 70 years. This approval strengthens Roche's strategic pivot of Gazyva from oncology to autoimmune diseases, with ongoing FDA reviews for additional autoimmune indications.

This Wire brief sits within Fusion42's coverage of Biotech.